Sun Pharma to Introduce MSD, Ridgeback's Molnupiravir Under Brand 'Molxvir' in India For COVID-19 Treatment in Adults; DCGI Reviewing Clinical Data
Sun Pharmaceutical Industries on Thursday said it is gearing up to introduce Merck Sharp Dohme (MSD) and Ridgeback's molnupiravir under the brand name Molxvir in India. The Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir
New Delhi, November 12: Sun Pharmaceutical Industries on Thursday said it is gearing up to introduce Merck Sharp Dohme (MSD) and Ridgeback's molnupiravir under the brand name Molxvir in India. The Drugs Controller General of India (DCGI) is currently reviewing clinical data of molnupiravir for the treatment of COVID-19 in adults in India.
Earlier this year, Sun Pharma had signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply molnupiravir in India and to over 100 low- and middle-income countries. Molnupiravir is the first oral antiviral approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild-to-moderate COVID-19 in adults. Sun Pharma, Lupin Recall Products in US Market.
It is under review by the US Food and Drug Administration for the emergency use authorisation. "The recent authorisation of molnupiravir, licensed from MSD and Ridgeback, by the UK regulator is a positive step. "In line with our consistent efforts to accelerate access to new drugs for COVID-19 treatment, we are gearing up to make Molxvir available to patients and healthcare providers across India at an economical price post approval by DCGI," Sun Pharma India Business CEO Kirti Ganorkar said in a statement. Bharat Biotech's COVID-19 Vaccine Covaxin 77.8% Effective Against Coronavirus, Says Lancet Study.
Molxvir will be manufactured at one of the company's plants in India and it has enough capacity to meet the demand, he added. In the Phase-III trial by Merck, Molnupiravir significantly reduced the risk of hospitalisation or death by around 50 per cent in a planned interim analysis of the MOVe-OUT trial in at risk, non-hospitalised adult patients with mild-to-moderate COVID-19. Additionally, based on the participants with available viral sequencing data (around 40 per cent of participants), molnupiravir demonstrated consistent efficacy across viral variants like Gamma, Delta and Mu. HRS hrs
(This is an unedited and auto-generated story from Syndicated News feed, LatestLY Staff may not have modified or edited the content body)